RU2001124840A - Противоопухолевые антисмысловые последовательности, направленные на компоненты r1 и r2 рибонуклеотидредуктазы - Google Patents

Противоопухолевые антисмысловые последовательности, направленные на компоненты r1 и r2 рибонуклеотидредуктазы

Info

Publication number
RU2001124840A
RU2001124840A RU2001124840/15A RU2001124840A RU2001124840A RU 2001124840 A RU2001124840 A RU 2001124840A RU 2001124840/15 A RU2001124840/15 A RU 2001124840/15A RU 2001124840 A RU2001124840 A RU 2001124840A RU 2001124840 A RU2001124840 A RU 2001124840A
Authority
RU
Russia
Prior art keywords
antisense oligonucleotide
mammal
tumor cells
oligonucleotide according
sequence
Prior art date
Application number
RU2001124840/15A
Other languages
English (en)
Inventor
Джим А. РАЙТ (CA)
Джим А. РАЙТ
Эйпинг Х. ЯНГ (CA)
Эйпинг Х. ЯНГ
Original Assignee
Дженесенс Текнолоджиз Инк. (Ca)
Дженесенс Текнолоджиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженесенс Текнолоджиз Инк. (Ca), Дженесенс Текнолоджиз Инк. filed Critical Дженесенс Текнолоджиз Инк. (Ca)
Publication of RU2001124840A publication Critical patent/RU2001124840A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

1. Антисмысловой олигонуклеотид из менее чем примерно 50 нуклеотидов, включающий последовательность AS-I-618-20 [SEQ ID NO 176].
2. Антисмысловой олигонуклеотид по п. 1, проявляющий сниженную димеризацию и сниженные автокомплементарные взаимодействия.
3. Антисмысловой олигонуклеотид по п. 1 для подавления онкогенности опухолевых клеток у млекопитающего.
4. Антисмысловой олигонуклеотид по п. 1 для подавления онкогенности опухолевых клеток, резистентных к химиотерапевтическому лекарственному средству, у млекопитающего.
5. Антисмысловой олигонуклеотид по п. 1 для повышения чувствительности опухолевых клеток к химиотерапевтическому лекарственному средству у млекопитающего.
6. Антисмысловой олигонуклеотид по п. 1 для подавления метастазирования опухолевых клеток у млекопитающего.
7. Фармацевтическая композиция, включающая антисмысловой олигонуклеотид по любому из пп. 1-6 и фармацевтически приемлемый носитель или растворитель.
8. Выделенная ДНК с последовательностью, включающей участок инициации транскрипции и последовательность, кодирующую антисмысловой олигонуклеотид из менее чем примерно 50 нуклеотидов, включающий последовательность AS-I-618-20 [SEQ ID NO 176].
9. Применение антисмыслового олигонуклеотида по п. 1 для подавления роста опухолевых клеток у млекопитающего.
10. Применение фармацевтической композиции по п. 7 для подавления роста опухолевых клеток у млекопитающего.
11. Применение ДНК по п. 8 для подавления роста опухолевых клеток у млекопитающего.
12. Применение антисмыслового олигонуклеотида по любому из пп. 1-6 для производства лекарственного средства.
13. Применение ДНК по п. 8 для производства лекарственного средства.
RU2001124840/15A 1999-02-11 2000-02-09 Противоопухолевые антисмысловые последовательности, направленные на компоненты r1 и r2 рибонуклеотидредуктазы RU2001124840A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/249,730 US6121000A (en) 1999-02-11 1999-02-11 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US09/249,730 1999-02-11

Publications (1)

Publication Number Publication Date
RU2001124840A true RU2001124840A (ru) 2004-03-27

Family

ID=22944744

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001124840/15A RU2001124840A (ru) 1999-02-11 2000-02-09 Противоопухолевые антисмысловые последовательности, направленные на компоненты r1 и r2 рибонуклеотидредуктазы

Country Status (17)

Country Link
US (1) US6121000A (ru)
EP (1) EP1153128B8 (ru)
JP (1) JP4424857B2 (ru)
KR (1) KR20020013501A (ru)
CN (1) CN1345373A (ru)
AR (1) AR022583A1 (ru)
AT (1) ATE309346T1 (ru)
AU (1) AU780455B2 (ru)
BR (1) BR0008788A (ru)
CA (1) CA2366487A1 (ru)
DE (1) DE60023845T2 (ru)
ES (1) ES2259602T3 (ru)
IL (1) IL144727A0 (ru)
MX (1) MXPA01008137A (ru)
NZ (1) NZ514090A (ru)
RU (1) RU2001124840A (ru)
WO (1) WO2000047733A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593305B1 (en) * 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
MXPA04010282A (es) * 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP2006518344A (ja) * 2003-02-10 2006-08-10 ジェネセンス テクノロジーズ インク リボヌクレオチド還元酵素ｒ２を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用
EP1615943A4 (en) * 2003-04-18 2006-08-16 Univ Pennsylvania COMPOSITIONS AND METHODS FOR INHIBITING ARNIC OF ANGIOPOIETIN 1 AND 2 AND THEIR TIE2 RECEPTOR
CN1302936C (zh) * 2003-05-02 2007-03-07 精工爱普生株式会社 打印机
EP1636363A1 (en) * 2003-05-21 2006-03-22 GeneSense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005065719A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
CA2564868C (en) * 2004-04-28 2013-11-26 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
WO2007146953A2 (en) * 2006-06-12 2007-12-21 Exegenics, Inc., D/B/A Opko Health, Inc. Compositions and methods for sirna inhibition of angiogenesis
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
CA2745832A1 (en) 2008-12-04 2010-06-10 Opko Ophthalmics, Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
DE102019000490A1 (de) * 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5766855A (en) * 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators
WO1998005769A2 (en) * 1996-08-02 1998-02-12 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Also Published As

Publication number Publication date
WO2000047733A1 (en) 2000-08-17
EP1153128B1 (en) 2005-11-09
DE60023845D1 (de) 2005-12-15
EP1153128A1 (en) 2001-11-14
KR20020013501A (ko) 2002-02-20
ATE309346T1 (de) 2005-11-15
AR022583A1 (es) 2002-09-04
AU780455B2 (en) 2005-03-24
DE60023845T2 (de) 2006-08-10
JP4424857B2 (ja) 2010-03-03
CA2366487A1 (en) 2000-08-17
BR0008788A (pt) 2001-11-06
AU2529200A (en) 2000-08-29
EP1153128B8 (en) 2006-01-18
WO2000047733A9 (en) 2001-03-15
JP2003500006A (ja) 2003-01-07
ES2259602T3 (es) 2006-10-16
US6121000A (en) 2000-09-19
CN1345373A (zh) 2002-04-17
NZ514090A (en) 2005-01-28
IL144727A0 (en) 2002-06-30
MXPA01008137A (es) 2004-08-12

Similar Documents

Publication Publication Date Title
RU2001124840A (ru) Противоопухолевые антисмысловые последовательности, направленные на компоненты r1 и r2 рибонуклеотидредуктазы
RU2394041C2 (ru) Полимерные олигонуклеотидные пролекарства
JP2006500958A5 (ru)
US11840688B2 (en) Compositions and methods for inhibiting gene expression of Hif2alpha
WO1993012129A1 (en) Peptide nucleic acids and their effect on genetic material
Welch et al. Expression of ribozymes in gene transfer systems to modulate target RNA levels
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
AU2002214609A1 (en) Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
ATE309345T1 (de) Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
CA2520541A1 (en) Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
HUP0103465A2 (hu) A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok
HK1047437A1 (en) Gonadotropin releasing hormone receptor antagonists and their related methods of use.
JP2006503904A5 (ru)
WO1997020924A1 (en) A class of oligonucleotides, therapeutically useful as antitumoural agents
HK1044965A1 (zh) T細胞受體Vβ-DβVβ序列和檢測它的方法
HUP0004877A2 (en) Novel nucleotid sequences coding for the sdha, sdhb and sdhc genes
Cohen Informational drugs: a new concept in pharmacology
WO2000027858A1 (fr) Oligonucleotides antisens inhibant l'activite de la telomerase et leurs applications
HUP0200192A3 (en) Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction, their use in preparation of medicaments, medicaments and process for their preparation
WO1996018732A9 (en) Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides
CA2304313A1 (en) Composition and method for enhancing paracellular transport across cell layers
WO2002006318A3 (en) Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
RU2000122677A (ru) Олигонуклеотидные последовательности, комплементарные генам тиоредоксина или тиоредоксинредуктазы, и использование их для модуляции роста клеток
JPH11285391A (ja) 抗ｈｉｖ剤
RU2001116558A (ru) Носители нуклеиновых кислот и фармацевтические композиции для генной терапии